Education
About Us
Working with TipRanks
Follow Us
PTC Therapeutics (PTCT)
NASDAQ:PTCT
PTCT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$24.00 - $58.38
Previous CloseN/A
Volume146.45K
Average Volume (3M)783.50K
Market Cap
$4.51B
Enterprise Value$2.24B
Total Cash (Recent Filing)$548.36M
Total Debt (Recent Filing)$421.44M
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Apr 24, 2025EPS Estimate
-1.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.73
Shares Outstanding78,869,370
10 Day Avg. Volume785,212
30 Day Avg. Volume783,501
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.59
Price to Cash Flow (P/CF)-37.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.50
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.78
Enterprise Value/Ebitda-17.92
Forecast
1Y Price Target
$64.82Price Target Upside13.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
---
Bulls Say, Bears Say
Bulls Say
Drug Approval And Market PotentialThe FDA has fast tracked potential approval for vatiquinone, the company’s drug to treat Friedrich ataxia, providing some de-risking for the FA program.
Sales PerformanceQ3 revenue was $197MM beating consensus of $172MM driven by strong protection of Emflaza sales.
Strategic PartnershipsPTC signed an exclusive global license agreement with NVS for PTC518 in Huntington's disease in exchange for $1B upfront, up to $1.9B in development, regulatory and sales milestones, a 40/60 profit share in the U.S., and double-digit tiered royalties ex-U.S.
Bears Say
Competitive PricingPayor coverage for the PKU drug could be a challenge given cheap generic alternatives and management commentary suggesting pricing at a premium to branded competitors.
Financial PerformancePTC announced a Q3 net loss of $106.7MM or $1.39/share, which was higher than the estimated net loss.
Regulatory ChallengesTranslarna's negative opinion from CHMP poses a risk, and remaining on the EU market appears tenuous.
---
Ownership Overview
1.36% Insiders
26.37% Mutual Funds
32.27% Other Institutional Investors
22.84% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PTCT FAQ
What was PTC Therapeutics’s price range in the past 12 months?
PTC Therapeutics lowest stock price was $24.00 and its highest was $58.38 in the past 12 months.
What is PTC Therapeutics’s market cap?
PTC Therapeutics’s market cap is $4.51B.
When is PTC Therapeutics’s upcoming earnings report date?
PTC Therapeutics’s upcoming earnings report date is Apr 24, 2025 which is in 30 days.
How were PTC Therapeutics’s earnings last quarter?
PTC Therapeutics released its earnings results on Feb 27, 2025. The company reported -$0.85 earnings per share for the quarter, missing the consensus estimate of -$0.54 by -$0.31.
Is PTC Therapeutics overvalued?
According to Wall Street analysts PTC Therapeutics’s price is currently Undervalued.
Does PTC Therapeutics pay dividends?
PTC Therapeutics does not currently pay dividends.
What is PTC Therapeutics’s EPS estimate?
PTC Therapeutics’s EPS estimate is -1.02.
How many shares outstanding does PTC Therapeutics have?
PTC Therapeutics has 78,869,370 shares outstanding.
What happened to PTC Therapeutics’s price movement after its last earnings report?
PTC Therapeutics reported an EPS of -$0.85 in its last earnings report, missing expectations of -$0.54. Following the earnings report the stock price went up 9.274%.
Which hedge fund is a major shareholder of PTC Therapeutics?
Currently, no hedge funds are holding shares in PTCT
---
PTC Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$64.82 (13.44% Upside)
$64.82 (13.44% Upside)
Blogger Sentiment
Bullish
PTCT Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.5%
Last 30 Days ▼ 16.5%
Last 30 Days ▼ 16.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
89.39%
12-Months-Change
Fundamentals
Return on Equity
33.08%
Trailing 12-Months
Asset Growth
-9.79%
Trailing 12-Months
Company Description
PTC Therapeutics
PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically-differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.
---
PTCT Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
PTC Therapeutics had a strong 2024 with notable financial performance, successful regulatory achievements, and strategic partnerships. However, there are challenges and uncertainties in regulatory approvals and market conditions that may impact future performance.Read More>---
PTCT Stock 12 Month Forecast
Average Price Target
$64.82
▲(13.44% Upside)
Technical Analysis
Alnylam Pharma
―
BioMarin Pharmaceutical
―
Ionis Pharmaceuticals
―
Neurocrine
―
Sarepta Therapeutics
―
Best Analysts Covering PTCT
1 Year
1 Year Success Rate
15/17 ratings generated profit
1 Year Average Return
+38.96%
reiterated a buy rating 4 months ago
Copying Joel Beatty's trades and holding each position for 1 Year would result in 88.24% of your transactions generating a profit, with an average return of +38.96% per trade.
---